“Emedica: A Noninvasive Device to Improve Insulin Sensitivity in Type 2 Diabetes Patients”.
Abstract
Insulin resistance is a key factor in the pathogenesis of type 2 diabetes mellitus (T2DM). This study is aimed to evaluate the effect of eMedica, a noninvasive device working on frequency-modulated electrical current therapy, in fat reduction and improved insulin sensitivity in type 2 diabetic patients. A cross-sectional study design was employed to evaluate alterations in insulin resistance, heart health, and the functioning of cells through statistical analysis in cohort of 25 patients with T2DM. The dataset provided insights into the glucose levels and insulin measurements of participants. The mean blood sugar level before and after intervention with eMedica therapy is 151.14 mg/dl, dropping significantly to 58.30 mg/Dl after therapy by e-Medica. These findings can help tailor diabetes management strategies and contribute to further analysis of participants' health profiles and treatment responses. This drop in the blood sugar levels after using eMedica therapy is prominent finding which can be used in routine management of the patients.
References
2. Solis-Herrera C, Triplitt C, Cersosimo E, et al. Pathogenesis of Type 2 Diabetes Mellitus. [Updated 2021 Sep 27]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279115/
3. Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:// www. ncbi. nlm.nih. gov/books/NBK507839/
4. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006 May;29(5):1130-9. doi: 10.2337/diacare.2951130. PMID: 16644654.
5. National Center for Chronic Disease Prevention and Health Promotion; Diabetes May 15, 2024.
6. Wu P, Wang X. Natural Drugs: A New Direction for the Prevention and Treatment of Diabetes. Molecules. 2023 Jul 20;28(14):5525. doi: 10.3390/molecules28145525. PMID: 37513397; PMCID: PMC10385698.
7. Krusche-Mandl I, Kaider A, Starlinger J, Preschitz M, Schuster R, Kefurt R, Marhofer P, Kasparek M, Hajdu S, Sator-Katzenschlager S. Implementation of Electrical Auricular Acupuncture and Low Frequency Modulated Electric Current Therapy in Pain Management of Patients with Knee Osteoarthritis: A Randomized Pilot Trial. J Clin Med. 2019 Aug 15;8(8):1229. doi: 10.3390/jcm8081229. PMID: 31443284; PMCID: PMC6723024.
8. Nagpal, Dr. (2023). Emedica: A New Approach To Diabetes Management. Journal for ReAttach Therapy and Developmental Diversities. 6. 1011-1016. 10.53555/jrtdd.v6i8s.3155.
9. Dr Deepak Nagpal, Hemant Rohera. Evaluating The Efficacy Of Emedica: A Cross-Sectional Analysis Of Its Role In Hypertension Management. Afr. J. Biomed. Res. Vol. 27(2) (May 2024); 01-08 doi.org /10.53555 /AJBR .v27i1S.1721
10. Dr Pratik Sheshrao Hande, Hemant Rohera, Dr. Gulam Saidunnisa Begum, Dr Deepak Nagpal, Dr Srinivasa Gowda, Dr B K Manjunatha Goud. Enhancing Patient Outcomes with Emedica Technology in the Fight Against COVID-19: A Health and Medicine Approach. Afr. J. Biomed. Res. Vol. 27 (September2024); 2861-2878. doi.org/10.53555/AJBR.v27i1S.1919
